Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 412

1.

Five-Year Reoperation Rates and Causes for Reoperations Following Lumbar Microendoscopic Discectomy and Decompression.

Aihara T, Endo K, Sawaji Y, Suzuki H, Urushibara M, Kojima A, Matsuoka Y, Takamatsu T, Murata K, Kusakabe T, Maekawa A, Yamamoto K.

Spine (Phila Pa 1976). 2019 Aug 13. doi: 10.1097/BRS.0000000000003206. [Epub ahead of print]

PMID:
31415462
2.

The factors related to the poor ADL in the patients with osteoporotic vertebral fracture after instrumentation surgery.

Murata K, Matsuoka Y, Nishimura H, Endo K, Suzuki H, Takamatsu T, Sawaji Y, Aihara T, Kusakabe T, Maekawa A, Yamamoto K, Watanabe K, Kaito T, Terai H, Tamai K, Tagami A, Yoshii T, Harimaya K, Kawaguchi K, Kimura A, Inoue G, Nakano A, Sakai D, Hiyama A, Ikegami S, Ohtori S, Furuya T, Orita S, Imagama S, Kobayashi K, Kiyasu K, Murakami H, Yoshioka K, Seki S, Hongo M, Kakutani K, Yurube T, Aoki Y, Uei H, Ajiro Y, Takahata M, Endo H, Abe T, Nakanishi K, Watanabe K, Okada E, Hosogane N, Funao H, Isogai N, Ishii K.

Eur Spine J. 2019 Aug 10. doi: 10.1007/s00586-019-06092-0. [Epub ahead of print]

PMID:
31401687
3.

Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).

Tamiya M, Tamiya A, Hosoya K, Taniguchi Y, Yokoyama T, Fukuda Y, Hirano K, Matsumoto H, Kominami R, Suzuki H, Hirashima T, Uchida J, Morita M, Kanazu M, Sawa N, Kinoshita Y, Hara S, Kumagai T, Fujimoto D.

Invest New Drugs. 2019 Aug 7. doi: 10.1007/s10637-019-00843-y. [Epub ahead of print]

PMID:
31392549
4.

10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy.

Mori H, Suzuki H, Matsuzaki J, Masaoka T, Kanai T.

Digestion. 2019 Aug 6:1-7. doi: 10.1159/000501610. [Epub ahead of print]

PMID:
31387107
5.

Clinical features of hypermagnesemia in patients with functional constipation taking daily magnesium oxide.

Mori H, Suzuki H, Hirai Y, Okuzawa A, Kayashima A, Kubosawa Y, Kinoshita S, Fujimoto A, Nakazato Y, Nishizawa T, Kikuchi M.

J Clin Biochem Nutr. 2019 Jul;65(1):76-81. doi: 10.3164/jcbn.18-117. Epub 2019 Jul 1.

6.

How to select patients for antireflux surgery? The ICARUS guidelines (international consensus regarding preoperative examinations and clinical characteristics assessment to select adult patients for antireflux surgery).

Pauwels A, Boecxstaens V, Andrews CN, Attwood SE, Berrisford R, Bisschops R, Boeckxstaens GE, Bor S, Bredenoord AJ, Cicala M, Corsetti M, Fornari F, Gyawali CP, Hatlebakk J, Johnson SB, Lerut T, Lundell L, Mattioli S, Miwa H, Nafteux P, Omari T, Pandolfino J, Penagini R, Rice TW, Roelandt P, Rommel N, Savarino V, Sifrim D, Suzuki H, Tutuian R, Vanuytsel T, Vela MF, Watson DI, Zerbib F, Tack J.

Gut. 2019 Aug 2. pii: gutjnl-2019-318260. doi: 10.1136/gutjnl-2019-318260. [Epub ahead of print]

PMID:
31375601
7.

Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.

Edahiro R, Kanazu M, Kurebe H, Mori M, Fujimoto D, Taniguchi Y, Suzuki H, Hirano K, Yokoyama T, Morita M, Fukuda Y, Uchida J, Makio T, Tamiya M.

PLoS One. 2019 Jul 31;14(7):e0220570. doi: 10.1371/journal.pone.0220570. eCollection 2019.

8.

Second Asian Consensus on Irritable Bowel Syndrome.

Gwee KA, Gonlachanvit S, Ghoshal UC, Chua ASB, Miwa H, Wu J, Bak YT, Lee OY, Lu CL, Park H, Chen M, Syam AF, Abraham P, Sollano J, Chang CS, Suzuki H, Fang X, Fukudo S, Choi MG, Hou X, Hongo M.

J Neurogastroenterol Motil. 2019 Jul 1;25(3):343-362. doi: 10.5056/jnm19041. Review.

9.

Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients.

Mori H, Suzuki H, Omata F, Masaoka T, Asaoka D, Kawakami K, Mizuno S, Kurihara N, Nagahara A, Sakaki N, Ito M, Kawamura Y, Suzuki M, Shimada Y, Sasaki H, Matsuhisa T, Torii A, Nishizawa T, Mine T, Ohkusa T, Kawai T, Tokunaga K, Takahashi S.

Therap Adv Gastroenterol. 2019 Jul 4;12:1756284819858511. doi: 10.1177/1756284819858511. eCollection 2019.

10.

Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?

Tamiya M, Tamiya A, Suzuki H, Moriizumi K, Nakahama K, Taniguchi Y, Kunimasa K, Kimura M, Inoue T, Kuhara H, Nishino K, Hirashima T, Atagi S, Imamura F, Kumagai T.

Anticancer Res. 2019 Jul;39(7):3923-3929. doi: 10.21873/anticanres.13544.

PMID:
31262922
11.

A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma.

Masuhiro K, Koh G, Takata S, Nasu S, Takada H, Morita S, Tanaka A, Shiroyama T, Morishita N, Suzuki H, Okamoto N, Kawasumi H, Konishi C, Hirashima T.

Respir Med Case Rep. 2019 May 26;28:100862. doi: 10.1016/j.rmcr.2019.100862. eCollection 2019.

12.

Cancer Stem-Cell Marker CD44v9-Positive Cells Arise From Helicobacter pylori-Infected CAPZA1-Overexpressing Cells.

Tsugawa H, Kato C, Mori H, Matsuzaki J, Kameyama K, Saya H, Hatakeyama M, Suematsu M, Suzuki H.

Cell Mol Gastroenterol Hepatol. 2019 May 27. pii: S2352-345X(19)30070-0. doi: 10.1016/j.jcmgh.2019.05.008. [Epub ahead of print]

13.

Evaluation of the robustness of 3-dimensional conformal technique with MLC position control into the planning target volume in stereotactic body radiotherapy for lung cancer.

Saito M, Sano N, Kuriyama K, Komiyama T, Marino K, Aoki S, Maehata Y, Saito R, Suzuki H, Shibata Y, Ueda K, Onishi H.

Med Dosim. 2019 May 25. pii: S0958-3947(19)30060-3. doi: 10.1016/j.meddos.2019.04.007. [Epub ahead of print]

PMID:
31138512
14.

Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis.

Andersen H, Mantegazza R, Wang JJ, O'Brien F, Patra K, Howard JF Jr; REGAIN Study Group.

Qual Life Res. 2019 Aug;28(8):2255. doi: 10.1007/s11136-019-02204-x.

15.

Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition.

Kato M, Ota H, Okuda M, Kikuchi S, Satoh K, Shimoyama T, Suzuki H, Handa O, Furuta T, Mabe K, Murakami K, Sugiyama T, Uemura N, Takahashi S.

Helicobacter. 2019 Aug;24(4):e12597. doi: 10.1111/hel.12597. Epub 2019 May 20.

PMID:
31111585
16.

Neutrophil-activating Protein Polymorphism of Helicobacter pylori Determines the Host Risk of Dyspepsia.

Matsuzaki J, Tsugawa H, Kashiwazaki Y, Mori H, Yamamoto Y, Kameyama H, Masaoka T, Kanai T, Suzuki H.

Cell Mol Gastroenterol Hepatol. 2019 May 18. pii: S2352-345X(19)30066-9. doi: 10.1016/j.jcmgh.2019.05.004. [Epub ahead of print] No abstract available.

17.

Clinical and endoscopic findings to assist the early detection of duodenal adenoma and adenocarcinoma.

Matsuzaki J, Suzuki H, Shimoda M, Mori H, Fukuhara S, Miyoshi S, Masaoka T, Iwao Y, Kanai Y, Kanai T.

United European Gastroenterol J. 2019 Mar;7(2):250-260. doi: 10.1177/2050640618817689. Epub 2018 Dec 3.

18.

A combination of serum anti-Helicobacter pylori antibody titer and Kyoto classification score could provide a more accurate diagnosis of H pylori.

Nishizawa T, Sakitani K, Suzuki H, Yamakawa T, Takahashi Y, Yamamichi N, Watanabe H, Seto Y, Koike K, Toyoshima O.

United European Gastroenterol J. 2019 Apr;7(3):343-348. doi: 10.1177/2050640619825947. Epub 2019 Jan 15.

19.

Re-challenge chemotherapy in patients with sensitive relapse small-cell lung cancer and interstitial lung disease.

Nasu S, Suzuki H, Moriizumi K, Hara Y, Tanaka S, Takada H, Morita S, Tanaka A, Shiroyama T, Morishita N, Okamoto N, Hirashima T.

J Thorac Dis. 2019 Feb;11(2):514-520. doi: 10.21037/jtd.2019.01.26.

20.

Eculizumab improves fatigue in refractory generalized myasthenia gravis.

Andersen H, Mantegazza R, Wang JJ, O'Brien F, Patra K, Howard JF Jr; REGAIN Study Group.

Qual Life Res. 2019 Aug;28(8):2247-2254. doi: 10.1007/s11136-019-02148-2. Epub 2019 Mar 23. Erratum in: Qual Life Res. 2019 May 21;:.

Supplemental Content

Loading ...
Support Center